Case 16-2012

Cabot, Richard C.; Harris, Nancy Lee; Shepard, Jo-Anne O.; Rosenberg, Eric S.; Cort, Alice M.; Ebeling, Sally H.; Peters, Christine C.; Baselga, Jos�; Smith, Barbara Lynn; Rafferty, Elizabeth A.; Bombonati, Alessandro
May 2012
New England Journal of Medicine;5/24/2012, Vol. 366 Issue 21, p2018
Academic Journal
Case Study
The article describes the case of a 32-year-old woman who was diagnosed with infiltrating ductal carcinoma of the right breast. Prior to her admission, the patient has observed a crease in the upper outer portion of her right breast. A mass was detected via mammography and ultrasonography. Information on her medical history is provided. Her immunohistochemical staining showed strong overexpression of the human epidermal growth factor receptor 2. Trastuzumab is the recommended treatment option.


Related Articles

  • Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer.  // World Journal of Surgical Oncology;2009, Vol. 7, p83 

    Background: The concordance rate between IHC and FISH according to clinical performance is still controversial. We report a prospective study to reflect the concordance between IHC and FISH in Guilin city, People's Republic of China. Methods: Fifty cases of invasive ductal carcinoma of breast...

  • External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale. Terrenato, Irene; Arena, Vincenzo; Pizzamiglio, Sara; Pennacchia, Ilaria; Perracchio, Letizia; Buglioni, Simonetta; Ercolani, Cristiana; Sperati, Francesca; Costarelli, Leopoldo; Bonanno, Elena; Baldini, Daniela; Candia, Silvia; Crescenzi, Anna; Dal Mas, Antonella; Di Cristofano, Claudio; Gomes, Vito; Rosalba Grillo, Lucia; Pasquini, Paola; Pericoli, Maria Nicoletta; Ramieri, Maria Teresa // Journal of Experimental & Clinical Cancer Research (17569966); 

    Background: An External Quality Assessment (EQA) program was developed to investigate the state of the art of HER2 immunohistochemical determination in breast cancer (BC) in 16 Pathology Departments in the Lazio Region (Italy). This program was implemented through two specific steps to evaluate...

  • SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients. D'Alfonso, Timothy Michael; Yi-Fang Liu; Zhengming Chen; Ying-Bei Chen; Cimino-Mathews, Ashley; Shin, Sandra Jean // Journal of Clinical Pathology;May2013, Vol. 66 Issue 5, p409 

    Accurate assessment of HER-2/neu gene status in breast cancer patients has important prognostic and therapeutic implications. Overexpression/gene amplification of HER-2 is associated with a more aggressive clinical course and eligibility for targeted therapy with trastuzumab. A variety of...

  • HER2-positive breast cancer metastatic to intracranial meningioma: a case report. McCormack, Mikkaela; Salinas-La Rosa, Cesar; Murphy, Michael; Fox, Stephen B. // Journal of Clinical Pathology;Jul2013, Vol. 66 Issue 7, p633 

    The article describes the case of HER2-positive breast cancer metastatic to intracranial meningioma. The successful introduction of trastuzumab and other novel tyrosine kinase inhibitors (TKI) for the treatment of HER2-positive breast carcinoma has resulted in lengthened survival for the...

  • Trastuzumab tallies up in HER2+ breast cancer. Pene, Stacey // PharmacoEconomics & Outcomes News;11/17/2007, Issue 541, p7 

    Breast cancer is the most common cause of malignancy-related death among women. Poor prognosis among such patients is associated with pathological features such as tumour size, histological grade and node involvement. In the US, approximately 192 000 new cases of breast cancer are diagnosed each...

  • Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Emilio Bria; Federica Cuppone; Monica Fornier; Cecilia Nisticò; Paolo Carlini; Michele Milella; Edmondo Terzoli; Francesco Cognetti; Diana Giannarelli // Breast Cancer Research & Treatment;May2008, Vol. 109 Issue 2, p231 

    Abstract   Background In five randomized clinical trials (RCTs), adjuvant trastuzumab (T) for early stage breast cancer with human epidermal growth-factor receptor-2 over-expression/gene-amplification has shown to decrease the risk of both recurrence and death. The issue regarding the...

  • Not quite pharmacogenomics. Haseltine, William A. // Nature Biotechnology;Dec98, Vol. 16 Issue 13, p1295 

    Reports that the use of diagnostic test which detect overexpression of the HER2 antigen to identify breast cancer patients likely to benefit from Herceptin lack pharmacogenomics. Usage of the genotype to segregate responding from non-responding patients; Measurement of a phenotype unlinked to...

  • Cochrane Library: Balancing trastuzumab's survival benefits and heart risks for women with breast cancer.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article focuses on a study, in which researchers found that trastuzumab increases the chance of prolonged life and reduces the chance of tumors reappearance after the therapy is stopped when added to the treatment offered to women who have HER2-positive breast cancer.

  • Patterns of HER-2/neu Amplification and Over-expression in Primary and Metastatic Breast Cancer. Simon, Ronald; Nocito, Antonio; Hübscher, Tanja; Bucher, Christoph; Torhorst, Joachim; Schraml, Peter; Bubendorf, Lukas; Mihatsch, Michael M.; Moch, Holger; Wilber, Kim; Schötzau, Andreas; Kononen, Juha; Sauter, Guido // JNCI: Journal of the National Cancer Institute;8/15/2001, Vol. 93 Issue 16, p1141 

    Investigates the patterns of HER-2 gene amplification and overexpression in primary and metastatic breast cancer. Response of patients on trastuzumab treatment; Application of tissue macroarrays in the study; Result of the fluorescence in situ hybridization and immunohistochemistry analysis...


Read the Article


Sign out of this library

Other Topics